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1. Research Proposal 
1.1.  Background 
Neonatal sepsis or septicaemia describes the systemic response to infection and/or the 
isolation of bacteria from the bloodstream in the first 28 days of life.1 Neonatal sepsis 
contributes significantly to the morbidity and mortality burden among term and preterm 
neonates, particularly in developing countries. The World Health Organisation (WHO) 
estimates that 10% of all under-five mortality is due to neonatal sepsis.2 Infection rates 
prove to be higher with decreasing birth weight and gestational age. 3 Neonatal sepsis not 
only presents a mortality risk but also a grave morbidity risk as it has been associated with 
cerebral white matter damage in term and preterm infants.3 Culture-proven septicaemia 
has been shown to increase the rate of several neurodevelopmental and growth 
outcomes, including: delayed mental and psychomotor development; vision and hearing 
impairment; cerebral palsy; poor weight gain, and poor head growth.3 In order to reduce 
brain injury associated with infection, interventions such as: earlier diagnosis; stabilising 
blood pressure; maintaining adequate oxygenation; reducing systemic inflammation and 
generation of proinflammatory cytokines, as well as pharmacological therapies, may 
reduce the impact of oxygen free radicals on vulnerable oligodendroglial precursors.3 Not 
only does the infection itself pose problems for long-term growth and development, but 
prolonged and high drug levels of aminoglycoside therapy are known to cause 
ototoxicity.3 
Neonatal sepsis has been classified into early onset and late onset sepsis. This 
classification assists us in identifying the most likely organisms to be implicated, the mode 
of transmission and guides us in instituting the appropriate antibiotic therapy.4 Early 
onset neonatal sepsis is defined as infection from birth to 72 hours of life and is mostly 
due to transplacental infection or an ascending infection from the maternal cervix caused 
by microorganisms colonising the genitourinary tract. The occurrence of early onset 
neonatal sepsis is associated with multiple risk factors, which include but are not limited 
to low birth weight, prolonged rupture of maternal amniotic membranes prior to delivery, 
foul-smelling amniotic liquor, multiple vaginal examinations, maternal fever, difficult or 
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prolonged labour and aspiration of meconium.5 Late onset neonatal sepsis occurs after 72 
hours of life as a result of horizontal transmission of organisms, mostly those that thrive 
in the home or hospital. The presentation is usually as septicaemia, pneumonia or 
meningitis. Risk factors associated with late onset neonatal sepsis are infants’ low birth 
weight or low gestational age, the need for mechanical ventilation, the use of parenteral 
nutrition, previous antimicrobial exposure, lack of human milk feeding, the presence of 
superficial infections and aspiration of feeds. Additionally, breaks in barrier defense by 
frequent needle pricks causing loss of skin integrity, the presence of indwelling central 
venous catheters or intravenous lines and inadequate hand hygiene practices of health 
care providers, play a significant role.5 
Neonatal sepsis signs and symptoms are often non-specific, non-sensitive and subtle. 
These include: fever or hypothermia, apnoea, cyanosis, feeding difficulties, lethargy or 
irritability, hypotonia, seizures, bulging fontanelle, poor perfusion, coagulopathy, 
abdominal distension, hepatomegaly and jaundice.4 Early warning signs and symptoms 
may be confused with non-infective causes, which include apnoea of prematurity, 
variation in environmental temperature and an acute exacerbation of chronic lung 
disease.6 Even though the onset of sepsis may not immediately be apparent, the effects 
of not providing early diagnosis and treatment may lead to septic shock, disseminated 
coagulopathy and rapid progression to death.6 
Laboratory sepsis markers alongside the evaluation of clinical signs and risk factors are 
important in diagnosing neonatal sepsis. Isolation of bacteria from blood is considered to 
be the gold standard for diagnosing sepsis.4 Common pathogens implicated in neonatal 
sepsis include: gram positive organisms (S. epidermidis, S. aureus and Enterococcus 
species), gram negative bacilli (K. pneumoniae and Pseudomonas aeruginosa) as well as 
fungal pathogens (usually Candida). Multidrug resistant organisms are becoming 
increasing prevalent and pose antibiotic challenges. These organisms include methicillin-
resistant S. aureus, vancomycin-resistant enteroccoci, pan-resistant Acinetobacter and 
extended spectrum beta-lactamase (ESBL) and cabapenemase-producing gram-
negatives.7 Blood culture results are usually only available 24 to 48 hours later and if 
negative do not exclude sepsis. Since sepsis may run a fulminant course if not treated 
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early, antibiotic therapy is usually instituted without waiting for blood culture results. 0.5 
to 1 ml of blood taken for culture decreases its sensitivity, as about 60 to 70 % of infants 
have a low level of bacteraemia.4 To ensure optimal results approximately 6 ml of blood 
would be required for inoculation, but in neonates this is not feasible.4 A positive culture 
may also arise as a result of asymptomatic bacteraemia or contamination. Procedures 
that improve blood culture sensitivity and specificity include proper skin disinfection prior 
to blood sampling, appropriate volume of blood per culture, culturing early in the septic 
episode and if culturing through an existing intravenous device, a peripheral blood culture 
should also be collected.5   
Although blood cultures are the gold standard of diagnosis in sepsis, they pose many 
diagnostic dilemmas, necessitating the need for a diagnostic test with both positive and 
negative predictive value. The ideal diagnostic test in the neonatal period should be 
sufficiently sensitive for infected neonates not to remain untreated but specific enough to 
allow rational antibiotic prescription and have predictive negative value to allow safe 
withholding or discontinuation of antibiotics.8 It is important to note that the most 
appropriate and ideal biomarker has not yet been established. Usually broad spectrum 
antibiotics are prescribed due to low culture positive rates. These have the potential to 
disturb commensal flora and have been associated with the emergence of multidrug 
resistant gram negative bacilli and the development of invasive candidiasis.9 In early 
onset neonatal sepsis in extremely low birth weight infants, prolonged empiric antibiotic 
usage has been associated with higher risk of death and necrotising enterocolitis.9  
Furthermore, the adverse effects of antibiotic therapy may be nephrotoxicity, 
hepatotoxicity, haematological abnormalities and blood sampling for drug level 
monitoring.9 Ultimately the ideal infection diagnostic test should require a small volume 
of specimen, be inexpensive, easy to carry out, provide rapid results, allow differentiation 
between causative agents and comparisons between laboratories.8 
The C-reactive protein (CRP) is one of the most studied and most used laboratory 
indicators for neonatal sepsis. It is an acute phase reactant synthesised by the liver. It 
rises rapidly within four to six hours of an inflammatory process and has a half life of 24 to 
48 hours.4 It takes up to 12 hours to change significantly after the onset of infection and 
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has a low sensitivity in the early phase of sepsis.4,10 CRP results greater than 10 mg/L are 
considered positive in most literature, irrespective of gestational or postnatal age.2 Any 
elevation of serum CRP in the neonate always represents endogenous synthesis as it 
crosses the placenta in very low quantities.10 Studies have shown that sensitivities and 
specificities for CRP range from 74-98% and 71-94% respectively.10 Serial CRP 
measurements have been highlighted as useful in identifying neonates who do not have 
bacterial infection. A repeat CRP 48 hours post antibiotic initiation has a 99% negative 
predictive value in accurately identifying neonates uninfected.10 Serial measurements are 
useful for reviewing the response to antibiotics, the duration of antibiotic therapy, and to 
recognise potential complications. Unlike blood cultures, CRP measurement is unaffected 
by prior antibiotic therapy. It is important to note that other non-infectious conditions 
such as meconium aspiration syndrome, traumatic or ischaemic tissue injuries, 
haemolysis or chorioamnionitis, also cause elevation in CRP levels.    
There are many other tests that may be performed to assist in diagnosing neonatal sepsis. 
The complete or full blood cell count (FBC) is one of these tests and is rapid, inexpensive 
and widely available. The diagnostic accuracy of the aforementioned test is not well-
defined in the neonatal setting and may be affected by physiological changes, especially 
in very low birth weight infants.11 High and low white blood cell counts, high absolute 
neutrophil counts, high immature-to-total neutrophil ratios and low platelet counts are 
associated with late onset neonatal sepsis.11 However, a high proportion of infants with 
late onset sepsis have normal full blood counts and no full blood count index can reliably 
rule out infants with late onset sepsis.11 Procalcitonin or PCT is another biomarker of 
neonatal sepsis. It is an acute phase reactant produced by both hepatocytes and 
macrophages. The serum concentrations of PCT start to increase four hours post 
exposure to bacterial endotoxins and peak within six to eight hours, remaining elevated 
for at least 24 hours.4  At 48 hours serum concentrations of PCT return to baseline. In 
non-infected neonates PCT concentrations tend to vary widely and PCT has its limitations. 
In the absence of true neonatal infection, PCT may in fact be increased in: newborns 
requiring neonatal resuscitation; infants born to mothers with chorioamnionitis; maternal 
Group B streptococcal colonisation, and prolonged rupture of membranes.4 Additionally 
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the use of PCT is limited by its physiological surge which reaches peak levels at 24 hours 
of age in preterm and term neonates. This suggests that PCT has better diagnostic 
accuracy for late onset sepsis in comparison to early onset sepsis.12 A meta-analysis 
showed high statistical heterogeneity for all analyses of PCT with variable sensitivity and 
specificity across studies.12 While PCT may be more sensitive than CRP, it is not sensitive 
enough to avoid antibiotic therapy.12 It is important to note that PCT values were found 
to reduce more quickly with treatment than CRP values.8 When considering diagnostic 
testing and expenses, PCT proves to be a more expensive test than CRP.  
At Groote Schuur Hospital’s neonatal unit clinical signs as well as FBC and CRP are pivotal 
in directing management for neonatal sepsis. C-reactive protein is requested for both 
early onset and late onset sepsis and is considered positive if more than 10 mg/L. 
Antibiotics are initiated as soon as the neonate is thought to have sepsis and once a blood 
culture has been performed. C-reactive protein is done in all neonates with suspected 
sepsis. At this neonatal unit the clinician performs blood sampling for CRP and the blood 
is sent to the laboratory for standard laboratory measurement by the Cobas 6000 
analyser. Once antibiotics are started the duration of treatment is tailored to clinical 
circumstances. If the initial CRP is below 10 mg/L, a second blood sample is sent for CRP 
48 hours after antibiotic initiation. Blood cultures that remain negative after 48 hours, 
along with the repeat CRP below 10 mg/L prompt the cessation of antibiotic therapy in 
patients who no longer exhibit clinical signs of sepsis. The neonatal unit protocol prohibits 
routine courses of antibiotic therapy in the absence of proven or strong suspicion of 
sepsis.13 
C-reactive protein measurement can be performed using standard laboratory 
measurement or alternatively a point of care analyser. This research study will be carried 
out at Groote Schuur Hospital’s neonatal unit, where the National Health Laboratory 
Service (NHLS) uses the Roche Cobas 6000 analyser for standard laboratory measurement 
of CRP. The Cobas 6000 system has been found to accommodate robust chemistry and 
immunochemistry, and has good potential for workstation consolidation in medium-sized 
laboratories.14 This analyser in comparison to other leading laboratory analysers has been 
shown to provide excellent precision data and result equivalence for most assays.14 This 
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system utilises an automated particle enhanced immunoturbidimetric assay. The reagent 
used contains latex spheres that are coated with monoclonal anti-CRP antibody. The 
antibody is raised to the CRP to agglutinate. Light is passed through the sample and may 
be scattered, reflected or absorbed. Immunoturbidimetry measures the absorbance of 
light from the sample. This determines a quantitative CRP result, as the anaylate 
concentration is inversely proportional to the light signal.2 The result is considered 
positive if more than 10mg/L. This conventional method of obtaining CRP requires 
collection of blood in a 400 µl microtainer which is then sent to an offsite laboratory. The 
cost of each CRP test is more than R65.   
Point of care testing (POCT) is defined as medical testing at or near the site of patient 
care. It allows for smaller blood volume sampling, rapid availability of results, earlier 
therapeutic decision making and may in fact be more cost effective when compared to 
standard laboratory measurement. This research study will be using the Alere AfinionTM 
point of care CRP test, which is a solid phase immunochemical assay requiring an analyser 
and test cartridges. This test requires only 1.5 µl of blood, has a test time of 
approximately four minutes and its measuring range for CRP is 5-200 mg/L.15 Each CRP 
test cartridge costs approximately R50. This point of care test is a simple three step 
procedure that involves: 1) collecting the blood sample via clinician chosen standard 
sampling techniques, 2) collecting the blood using the self-contained capillary tube in the 
test cartridge that collects the exact volume of blood required for the test and, 3) 
inserting the test cartridge into the analyser to obtain a result. The test cartridge is placed 
in the analyser where it is automatically diluted with a liquid that lyses the blood cells. 
The sample mixture is passed through a membrane coated with anti-CRP antibodies. The 
CRP in this sample is concentrated onto this membrane. A solution containing anti-CRP 
antibodies conjugated with ultra-small gold particles is then passed through this 
membrane and the gold-antibody conjugate binds to the immobilised CRP on the 
membrane, which then turns red-brown. Excess gold-antibody is removed by a washing 
solution. The analyser measures the colour intensity of the membrane and it is this 
intensity that is proportional to the amount of CRP within the sample. The CRP 
concentration is then quantitatively displayed on the analyser screen.16 This POCT states 
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that a CRP of less than 5mg/L is found in healthy individuals and can reach between 20 
and 200mg/L in the presence of acute inflammation.16 
The AfinionTM point of care test procedure requires a minimal level of user-interaction, 
making it more user-friendly than the NycoCardTM and the QuickRead® point of care tests. 
The NycoCardTM point of care system requires additional manual steps by the user, such 
as dilution of the sample, applying a conjugate, washing the sample and finally reading 
the test result.15 Similarly the QuickRead® CRP point of care system requires a specific 
instrument, capillaries, cuvettes and reagents that require accurate measurement and 
mixing with a specific volume of blood sample to perform the test.2 The QuickRead® CRP 
requires additional and potentially complicated steps to carry out the test, these include: 
filling the capillaries with blood; dispensing the specimen into the cuvette containing a 
1ml buffer; closing the cuvette with the CRP-reagent cap containing the CRP-reagent and 
mixing it by gentle shaking; after mixing the cuvette is placed in the instrument-well to 
derive a control measure which takes 40 seconds; the cap containing the dried anti-
human CRP latex reagent is depressed, resulting in the reagent being released into the 
sample; the cuvette is then taken out of the instrument-well and gently remixed; the final 
step involves the sample being replaced in the instrument-well for the measurement of 
the CRP concentration.2 The choice of the AfinionTM point of care test in this study is 
supported by its simple use requiring just three steps and its minimal use of blood (only 
1.5µl in comparison to 5µl in the NycoCardTM system and 20µl in the QuickRead® 
system).17, 2 This ensures that staff training on the use of the point of care system is 
simple and quick to demonstrate within this busy neonatal unit, where both staff and 
patient turnover is high. In a paediatric and adult population the AfinionTM point of care 
test has shown great accuracy and precision when compared to standard laboratory 
measurement, however the results of this study could not be generalised to the neonatal 
population.15 This suggests the need for further studies of point of care CRP testing within 
the neonatal population. A further study looking at the QuickRead® point of care test 
suggested that it may be beneficial in resource-limited settings, where it may facilitate 
reduction in costs and earlier patient discharge.2 
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1.2. Purpose and Objectives 
1.2.1. Primary objectives 
The purpose of this study is to validate the Alere AfinionTM point of care test CRP in 
neonates with suspected sepsis at Groote Schuur Hospital’s neonatal unit using the CRP 
obtained from the National Health Laboratory System’s Roche Cobas 6000 as the 
reference test 
1.2.2. Secondary objectives 
1. To measure the potential change in antibiotic dosage exposure if management 
decisions regarding antibiotic therapy were made using CRP results obtained from 
the Alere AfinionTM CRP system when compared to standard NHLS laboratory testing 
2. To measure the ease of use of Alere AfinionTM by using time until test completion as a 
proxy measure 
1.3. Method 
1.3.1. Design 
The study design is that of a prospective observational study and diagnostic test 
evaluation.   
1.3.2. Sample 
Participants eligible for inclusion in the study will be neonates with suspected sepsis who 
are admitted to the Groote Schuur Hospital neonatal unit. An informal and unpublished 
audit performed at the Groote Schuur Hospital neonatal unit showed that approximately 
140 to 160 CRP laboratory tests are done per month.18 A total of at least 138 samples will 
be obtained for analysis. The sample size was calculated using Epicalc2000. The sample 
size was estimated to be 138 in order to ensure a sensitivity and specificity of 90% with a 
margin of error of +/- 5%. Patients will only be recruited during normal working hours. 
This sampling method was selected due to workforce limitations in both clinical and 
laboratory staff after hours. Clinicians involved in patient care within the unit will be 
performing the blood sampling. Blood will be drawn at the clinician’s discretion either 
through venepuncture or arterial puncture. Blood sampling for the standard laboratory 
measurement and the POCT test will be taken from the same blood sampling site. The 
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medical staff including the medical officers, paediatric registrars as well as the 
neonatology consultants will be making therapeutic decisions solely based on the 
standard laboratory measurement result and not on the POCT result.  
Inclusion criteria: any neonate in whom the CRP will be done either as part of a septic 
work up or follow up test. This CRP must be analysed by both the Alere AfinionTM point of 
care CRP analyser and the standard laboratory Cobas 6000 analyser. Parental informed 
consent must be obtained for inclusion of the participant in the study.  
Exclusion criteria: any neonate in whom the Alere AfinionTM CRP result or standard 
laboratory CRP result will not be available. Neonates will be excluded should parental 
consent not be granted.   
1.3.3. Data 
Patient names and hospital numbers will be used to identify samples. Data will be 
collected with the use of a pre-designed data collection sheet (see addendum 1). This 
sheet will be completed by the doctor who has taken the blood sample for both the Alere 
AfinionTM CRP measurement and standard laboratory measurement. It is the 
responsibility of the clinicians caring for the patient to obtain informed consent. Doctors 
working within the Groote Schuur Hospital Neonatal Unit will be trained to use the point 
of care test and instructed as to how to complete the data collection sheet. The clinicians 
will be instructed to telephonically contact the primary investigator of all new cases daily 
and a formal record book noting the patient details and time of test will be kept within 
the unit. If consent cannot be obtained prior to performing the POCT then the patient will 
be excluded from the study. Data collection sheets will be kept within the patient’s folder 
until the primary investigator is able to collect the sheets. CRP results will be verified by 
reviewing the standard laboratory measurement result on the NHLS computer results and 
the POCT by reviewing the records on the analyser. The POCT CRP result will not be used 
to determine patient management. Clinicians will obtain both results but will only base 
clinical decisions on the standard laboratory measurement result. The laboratory staff 
and technicians will be unaware of this study and will be expected to process results as 
usual.    
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Data from the data collection sheet will be captured and synthesised in Microsoft Excel 
spreadsheets. The hard copies of data collection sheets will be kept in a file in a lockable 
cabinet, which will only be accessible to the researchers. Collated data will be kept in a 
password protected Microsoft Excel spreadsheet.   
The data collection sheet will include: 
• Patient demographic details 
• Risk factors for sepsis 
• Signs and symptoms indicating possible sepsis 
• Reason for requesting a CRP 
• Whether a blood culture and other cultures were taken or not taken  
• Whether empiric antibiotic therapy was initiated  
• Time from blood sampling to obtaining point of care result 
• Time of CRP laboratory results being released on NHLS result system 
• Time from blood sampling to obtaining standard laboratory measurement result 
• CRP results from both POCT and standard laboratory measurement 
Blood culture results and duration of antibiotic therapy will be followed up by the 
researcher. The time that the clinician first becomes aware of the result will be recorded 
as the time to result. The time it takes to perform the AfinionTM test will be noted for 
comparison. Clinicians must always document the time that the sample was taken. 
1.3.4. Analysis 
Standard statistical methods will be utilised through the statistical software package, 
Stata. The primary objective will be analysed using receiver operator characteristic curves 
and Bland-Altman Plot. This will provide graphical representation of the true positive rate 
versus the false positive rate when comparing the point of care CRP to the gold standard 
NHLS CRP and analyse the agreement between the two measures. The sensitivity, 
specificity, positive predictive values and negative predictive values will be analysed using 
the laboratory CRP test as a reference. The p-value will be considered statistically 
significant if less than or equal to 0.05. When comparing categorical variables, such as 
blood culture samples to the point of care test, the chi-squared or Fisher’s exact test will 
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be used to analyse this data. Other descriptive variables will be described in terms of 
means, medians, interquartile ranges, proportions and 95% confidence intervals. 
Statistical support will be obtained from the School of Public Health and Family Medicine 
during data collection and analysis. 
1.4. Timeline 
The research study from start to completion involves the following process and 
timeframe: 
• Proposal and synopsis writing - 3 months 
• Submission to Departmental Research Committee (DRC) and Faculty of Health Sciences 
Human Research Ethics Committee (HREC) - 2 months 
• Data collection - 3 to 4 months 
• Data analysis - 2 months 
• Thesis write up - 4 months 
1.5. Dissemination Plan 
The results of this study will primarily be included in a MMED dissertation. The research 
data will be presented at the School of Child and Adolescent Health Research Day. 
Furthermore the results of this study will be formatted as a journal article so that it may 
be suitable for publication in a peer-reviewed journal. 
1.6. Costs 
The cost of this study is estimated to be approximately R 16 000.   
The budgetary requirements include (addendum2): 
• Point of care test and control kits 
• Printing of data collection sheets  
• Office consumables 
• Research assistant 
Alere Healthcare Company will provide the AfinionTM AS100 Analyser for the duration of 
the study. The analyser will remain the property of Alere Healthcare Company and will be 
returned to them on completion of the study. Test and control kits will be purchased 
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using a registrar research grant provided by the Department of Paediatrics. No extra costs 
will be incurred with respect to the standard laboratory measurement, as these tests will 
be performed irrespective of the study.  
1.7. Conflict of Interest 
There is no conflict of interest in terms of this study. This study is designed and will be 
preformed independently from the Alere Healthcare Company. The researcher is not 
employed by this organisation, or associated organisations and in no way will gain or lose 
financially from the results of this study. No long-term contracts will be entered into on 
behalf of Groote Schuur Hospital with Alere Healthcare Company and the placement of 
the analyser in the neonatal unit will only be for the purposes of this study. 
1.8. Ethical Considerations  
All patients will be enrolled with parental consent (see addendum 3). The information 
sheet and parental consent will be available in English, Afrikaans and Xhosa. Patients will 
be identified by their names and folder numbers. Patient clinical information will remain 
private and confidential. Only the clinicians and researchers will have access to the 
identifying data and clinical information of the patients. There is no risk to participating in 
this study. Participants who are already having blood drawn for standard laboratory 
testing will be included and a small volume of blood (1.5 µl) will be used for point of care 
testing. Blood sampling and point of care testing will be performed by experienced 
medical clinicians involved in patients’ care. Management of patients will be based on 
laboratory results and not point of care results, until this study is able to validate the 
point of care system for future use. Benefits may be access to rapid results and reduced 
antibiotic therapy exposure and hospital stay. Future point of care testing within the unit 
may benefit patients and the neonatal unit in this regard. Ethical approval will be 
obtained from the Faculty of Health Sciences Human Research Ethics Committee. 
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2. Literature Review 
2.1. Objectives 
1. To compare the C-reactive protein (CRP) to other diagnostic tests and biomarkers 
2. To review point of care CRP test studies’ outcomes and impact on management 
2.2. Search Strategy  
PubMed database was searched online. Three searches were performed: 
1. Main search:  
((((("Infant, Newborn"[Mesh] AND Humans[Mesh] AND infant[MeSH])) OR 
(((newborn OR neonate)) AND Humans[Mesh] AND infant[MeSH])) AND 
Humans[Mesh] AND infant[MeSH])) AND (((((((("Point-of-Care Systems"[Mesh] OR 
"Point-of-Care Testing"[Mesh])) OR point of care)) OR ((("Clinical Laboratory 
Services"[Mesh] OR "Automation, Laboratory"[Mesh])) OR ((laborator* OR lab))))) 
AND (("C-Reactive Protein"[Mesh]) OR ((C-Reactive Protein OR CRP)))) AND 
Humans[Mesh] AND infant[MeSH])  
Filters included were humans and infants from birth to 23 months. This search 
yielded 369 articles of which 70 were applicable to the study topic. 18 studies were 
excluded because they were not in English. 8 studies were not obtainable in full text. 
44 articles from this search were reviewed. 
 
2. (Alere OR Afinion) AND (CRP OR C reactive protein) yielded 7 articles, 5 of which 
were applicable to the study topic.  
 
3. Antibiotics AND (CRP OR c reactive protein) AND (newborn OR neonate) yielded 
791 articles and 28 articles were applicable and therefore reviewed for additional 
information. 
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2.3 Literature 
2.3.1.  Background and Epidemiology 
Neonatal sepsis is a major public health problem and an economic burden especially to the 
developing world. Three quarters of the 2.6 million neonatal deaths annually are early 
neonatal deaths occurring in the first 7 days of life - an overwhelming majority (99%) of 
which occur in low to middle-income countries.1 Neonatal sepsis is responsible for 10% of all 
under-five mortality, being the third leading cause of neonatal deaths, after prematurity and 
intrapartum related deaths (such as asphyxia). 1–3 The World Health Organisation (WHO) 
estimates that 42% of sepsis related neonatal deaths occur in the first week of life.1,2 
While neonatal sepsis is variably defined based on several clinical and laboratory 
parameters, it is essentially a clinical syndrome characterised by systemic signs of circulatory 
compromise caused by bacterial invasion in the bloodstream within the first month of life.2  
Wynn et al have stated that a static definition of sepsis is likely to be associated with 
limitations in diagnostic accuracy as sepsis is a dynamic, complex and heterogeneous 
condition.4 The signs and symptoms of neonatal sepsis are non-specific and are often subtle. 
These clinical features include cyanosis, apnoea, grunting, lethargy or irritability, hypotonia, 
bulging fontanelle, poor perfusion, petechiae, purpura, hypoglycaemia or hyperglycaemia, 
abdominal distension, hepatomegaly, unexplained jaundice or “just not looking right”.1,5–7   
Predisposing factors for neonatal sepsis are prematurity, male gender, prolonged rupture of 
membranes and chorioamnionitis, maternal colonisation with Group B Streptococcus, 
maternal urinary tract infection and perinatal asphyxia.6 Neonates, particularly preterm 
neonates, are at higher risk of infections than the rest of the paediatric population as they 
have immature immune systems. This may be as a result of poor innate immunity with 
impaired cytokine production, reduced expression of adhesion molecules in neutrophils and 
decreased response to chemotactic factors.1 Humoral immunity may be affected as 
transplacental passage of antibodies starts in the second trimester of pregnancy with rapid 
increase in the third trimester.1 Cytotoxic T cell activity may also be impaired and 
complement activity is half that of healthy adults.1,2 Recurrent blood sampling and invasive 
procedures further add to the disruption of neonates’ protective barriers. Advocating early 
initiation of breastmilk and increasing exclusive breastfeeding have been shown to 
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significantly reduce diarrhoea and acute respiratory tract infections.2 Breastmilk consists of 
secretory IgA, lysozymes, white blood cells and lactoferrin and encourages the growth of 
healthy lactobacilli, while reducing the growth of Escherichia coli and other pathogenic gram 
negative organisms.2 
Based on the timing of infection, neonatal sepsis is characterised by early onset neonatal 
sepsis (EONNS) and late onset neonatal sepsis (LONNS). These two classifications indicate 
the presumed mode of transmission, likely implicated organisms and initiation of antibiotic 
therapy. Epidemiologists define EONNS as culture positive infections within the first three 
postnatal days of life.8 Similarly Zea-Vera et al and Shah et al define EONNS as symptoms 
starting before 72 hours or within the first three days of life.1,5 Hisamuddin et al define 
EONNS as disease present during the first five to seven days of life.9 The first definition, as 
defined by epidemiologists, is more widely accepted. EONNS arises as a result of vertical 
transmission from mother to infant during the intrapartum period. LONNS is defined as 
symptoms occurring after the EONNS period, which is after 72 hours of life or the first three 
days of life, alternatively after the first week of life. LONNS is usually caused by nosocomial 
infection related to prolonged hospitalisation, mechanical ventilation, intravenous 
cannulation or central line placement, parenteral nutrition and antibiotic administration as 
well as poor hand hygiene practices. Zea-Vera and Ochoa describe common pathogens 
causing sepsis in developed and developing countries in tables 1 and 2.1 
Table 1  Common pathogens of neonatal sepsis in developed countries 
E.coli = Escherichia coli; S.aureus = Staphylococcus aureus; L.monocytogenes = Listeria monocytogenes; 
P.aureginosa = Pseudomonas aureginosa 
Zea-Vera A, Ochoa TJ. Challenges in the diagnosis and management of neonatal sepsis. Journal of Tropical Pediatrics [Internet]. 2015 [cited 
2016 June 2];61(1):1-13. Table 1, Common pathogens of neonatal sepsis in developed countries; p.3. Available from PubMed 
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Table 2 Common pathogens of neonatal sepsis in developing countries 
S.aureus = Staphylococcus aureus; E.coli = Escherichia coli; S.pneumonia = Streptococcous pneumonia 
Zea-Vera A, Ochoa TJ. Challenges in the diagnosis and management of neonatal sepsis. Journal of Tropical Pediatrics [Internet]. 2015 [cited 
2016 June 2];61(1):1-13. Table 2, Common pathogens of neonatal sepsis in developing countries; p.3. Available from PubMed 
Gerdes stipulates that the goals of the clinician in neonatal sepsis are to 1) develop a 
systematic approach to the diagnosis of sepsis based on the relative importance of known 
symptoms and risk factors, 2) miss no cases, 3) minimise the duration of antimicrobial 
treatment for those high risk infants who are uninfected, and 4) provide a safe observation 
protocol for the low risk newborn.6 While clinical information is usually adequate to start 
empiric antibiotic treatment, it is difficult to use this information alone to tailor therapy in 
terms of agents and duration of treatment.10   
2.3.2. C-Reactive Protein 
C-reactive protein (CRP) is an acute phase reactant that belongs to the pentraxins, a family 
of proteins structurally made up of five identical subunits to form a pentameric disc-like 
structure. It is synthesised in the liver and physiologically binds to phosphocholine 
expressed in dead and dying cells causing an initiatory burst to activate the complement 
system.11 It may be produced in different cells including hepatocytes, lymphocytes, 
monocytes, atherosclerotic plaques, neurons and some tumours but its plasma 
concentration is almost exclusively due to synthesis in hepatocytes.11 CRP was first 
described in 1930 by Tillet and Francis at Rockerfeller University and takes its name from 
the observation that it forms an insoluble complex with C- polysaccharide of Streptococcus 
pneumoniae.12,13 CRP rapidly increases in 4 to 6 hours after the inflammatory process and is 
duplicated in 8 hours, reaching a peak in 36 hours and has a half-life of 19 hours.11 Due to 
the delayed response to sepsis, the sensitivity of CRP elevation at the time of evaluation for 
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suspected sepsis is low, particularly in EONNS.13 Kumar et al reported the sensitivity for 
early onset proven sepsis and late onset proven sepsis was 88.9% and 98.2% respectively.14 
Lower cut off values for preterm neonates have been suggested after Hofer et al found CRP 
to be less reliable in early onset infections in preterm infants when compared to term 
newborns.15 Any elevation of CRP in the newborn is indicative of endogenous synthesis as it 
passes the placenta in exceedingly low quantities.12 The normal levels of CRP in newborn 
infants range from 2 to 5 mg/l and cut-off values reported in the literature range from 1.5 to 
20 mg/l but the consensus is that 10 mg/l is the upper limit of normal.12,16   
Elevated measures of CRP may be associated with conditions other than bacterial infections, 
namely viral infections, trauma, ischaemic tissue injuries, haemolysis, meconium aspiration 
syndrome, complicated labour and delivery, animal-derived surfactant administration, 
intraventricular haemorrhage and chorioamnionitis without invasive fetal or neonatal 
disease.13,16 Ohlin and colleagues determined that the five clinical signs of feeding 
intolerance, distended abdomen, low blood pressure, bradycardia and apnoea, together 
with CRP were statistically significantly associated with a positive blood culture.17 Both 
single measurements and serial measurements of CRP have been studied.   
Lacaze-Masmonteil et al conducted a study that explored the value of a single CRP 
measurement at 18 hours of age. They suggested that an elevated 18 hour CRP in isolation 
should not be used as a reason to prolong antibiotics as an 18 hour CRP was ≥10 mg/l in 
85.8% of uninfected newborns.16 Furthermore, for proven or possible EONNS there was a 
low CRP sensitivity possibly because of intrapartum maternal antibiotics and delayed rise in 
CRP in infected preterm neonates. Boonkasidecha and colleagues reviewed CRP levels 
obtained at the time of initial sepsis work up and 12 to 24 hours later and found the use of a 
serial CRP to be better than a single measurement.18 The second CRP had a higher sensitivity 
and negative predictive value (NPV) than the first CRP. The cut off points for CRP in this 
study were notably much lower than the universally accepted cut off of ≥10 mg/l. Budget 
constraints or lack of blood culture facilities promote the use of a single CRP measurement 
24 to 48 hours after the suspected sepsis.18 A decrease of CRP within 48 hours after birth 
indicates that infection is unlikely and antibiotics can be discontinued. This would reduce 
health care costs, facilitate earlier discharge, prevent complications of therapy and avoid 
family anxiety.19,20 CRP is a valuable tool for objective monitoring of the success and length 
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of treatment as it declines in response to effective antibiotic therapy.21 Defensive medical 
practice, lack of experience, uncertainty, “routine practice”, lack of awareness of the 
associated costs and use of protocols and guidelines has led to overutilisation of laboratory 
testing.22    
Two main technological advancements in diagnostic testing have been: 
 1) the development of point of care or bedside tests, with availability of miniaturised and 
portable machines for rapid testing even for complex measurements usually performed by 
sophisticated instruments in specialised laboratories, and 
 2) the development of new methods including the study of genomics, the production of 
proteins, lipids and metabolites.10   
A significant advantage of CRP over other biomarkers is that point of care testing is 
commercially available providing bedside measurements that are performed and obtained 
within minutes.   
2.3.3. Diagnostic tests and biomarkers for neonatal sepsis other than C Reactive Protein 
Blood culture 
The gold standard for the definitive diagnosis of sepsis is the blood culture test for bacteria. 
While this is the most reliable test available it is flawed. Wang et al note that the blood 
culture test can be negative for one in five subjects with sepsis.23 Kayange et al note that the 
neonatal blood culture positive rate ranges from 25-54%.24 Mishra et al reviewed studies 
that showed positive culture rates from 8-73% in the diagnosis of potential neonatal 
sepsis.25 However, the sensitivity and specificity of blood culture is dependent on timing of 
sampling, adequate disinfection of the phlebotomy site or indwelling catheter, sufficient 
blood volume sampling and inoculation of culture medium, which poses significant 
challenges in extreme preterm infants. Furthermore it may take 48 hours or longer to obtain 
a positive result.13 For this reason initiation of empiric treatment is a necessity and other 
diagnostic tests or biomarkers may be employed for guidance.     
Accurate biomarkers that aim to diagnose sepsis or indicate the evolution of the infectious 
processes may strengthen the clinician’s decisions regarding therapeutic management. 
According to the National Institute of Health a biomarker is defined as biological 
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characteristics objectively measured and used as a marker either of a normal or pathological 
biological pathway, or pharmacological response to a specific intervention.10 There are two 
categories of biomarkers: prognostic biomarkers, which stratify a patient’s risk of having a 
specific outcome independent of treatment and predictive biomarkers, which allow 
prediction of the potential benefits and risks of treatment.10 The ideal biomarker should be 
accurate and reproducible. This ensures that 100% of all patients with the disease are 
detected by the test (sensitivity) and 100% of all patients that do not have the disease have 
a negative test result (specificity).25 However, finding the ideal biomarker for neonatal sepsis 
has been difficult. Interpreting a biomarker can be problematic as measurements are 
affected by many factors namely a lack of standardisation between different methods and 
biological factors such as blood collection tubes and transport media, time from sampling to 
analysis, precision, reproducibility and threshold of measurement.10    
Haematological tests 
Haematological tests are frequently used to assist with diagnosing sepsis but may be weaker 
diagnostic tests than the previously mentioned biomarkers.26 The most utilised of these 
haematological tests include the white cell count, neutrophil count, immature to total 
neutrophil ratio (I:T ratio) and platelet count, which are quick, easy and inexpensive to 
perform. In the presence of normal haematological findings in newborns with clinical 
features of sepsis, it is not sufficiently reassuring to defer initiation of antimicrobial 
therapy.13 The performance of these tests was evaluated by Benitz in 298 neonates in the 
first month of life, his findings are summarised in table 3.13 
Table 3 Performance of haematological markers  
Haematological finding Sensitivity Specificity 
Positive 
predictive value 
(PPV) 
Negative 
predictive value 
(NPV) 
White cell count 44% 92% 36% 94% 
Platelet count 
≤ 150 000mm3 
22% 99% 60% 93% 
Increased I:T ratio 96% 71% 25% 99% 
Increased or decreased 
neutrophil count 
96% 61% 20% 99% 
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PCT 
Procalcitonin (PCT) is an amino acid protein, which is a precursor to calcitonin produced by 
the C-cells of the thyroid gland. 27 It is produced by the liver and macrophages with serum 
levels rising 4 to 6 hours after exposure to bacterial products.13 A spontaneous increase in 
PCT in the first day of life with peak at 24 to 36 hours after birth in healthy newborns and 
decrease thereafter have been documented.13 PCT concentrations rise in blood in 
accordance with the intensity of inflammatory reaction due to infection without increasing 
the level of calcitonin and have the potential to differentiate between sepsis and systemic 
inflammatory response syndrome (SIRS) resulting from sterile inflammation.27,28 PCT levels 
also increase in uninfected neonates with birth asphyxia, intracranial haemorrhage, 
pneumothorax or after resuscitation.28 PCT’s role as a biomarker in the diagnosis and 
prognosis of sepsis is ambiguous as the initial PCT may not be reliable but instead serial 
measurements may assist in monitoring sepsis outcomes and guide therapy to reduce 
antibiotic exposure without increasing mortality.27 In a study conducted by Kordeck, it was 
found that elevations in PCT were associated with gram positive, predominantly coagulase-
negative staphylococcus, and gram negative bacterial infections.29 This may be useful in 
determining those newborns infected with coagulase-negative staphylococcus as oppose to 
newborns with samples contaminated by the organism. While cost and availability may 
hinder utility of PCT in resource-limited countries, other limitations are establishing detailed 
age specific normative ranges, low sensitivity in EONNS and lack of specificity.13   
Cytokines 
Cytokines such as Il-6, IL-8 and TNF-alpha, are intracellular messengers that act via specific 
receptors on target cells and mediate the inflammatory response.30 Acute phase reactants 
are produced in response to these proinflammatory cytokines, therefore high levels of 
cytokines occur promptly after exposure to bacterial products, preceding the increase in 
acute phase reactants.28 IL-6 has a very short half-life with concentrations declining rapidly 
with therapy, becoming undetectable in most newborns within 24 hours.28 It has been 
proposed that the combination of measurements, for example IL-6 and CRP, may enhance 
the likelihood of an abnormal result when uncertain about the stage of illness at which the 
neonate is being evaluated.13 Limitations of the utility of cytokines in routinely diagnosing 
neonatal sepsis include methodological difficulties in their detection, absence of their 
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routine usage in all centres and increase in their levels in all non-specific infections and in 
shock.28 
CD64 
CD64 is a leucocyte surface antigen with a high affinity Fc receptor, which binds to IgG. 
These receptors are involved in the innate and adaptive immune response to stimulate 
phagocytosis or antibody-mediated cytotoxicity.27 CD64 only has highest diagnostic accuracy 
in neonates until 24 hours after suspected sepsis and is able to differentiate between sepsis 
and SIRS in various patient populations.27 Wang et al report CD64 to have superior 
diagnostic accuracy to the I:T ratio and CRP when detecting EONNS.23 CD64 testing can be 
done on the sample sent for the complete blood count, only requires 50 µl of blood for 
detection and can be made available within hours of performing the complete blood 
count.23 Laboratories in developed countries and in only some developing countries have 
flow cytometry to perform the test. 
A comparison of biomarkers 
Meem and colleagues reviewed PubMed, EMBASE and HINARI sources to conduct a 
structured literature search on existing biomarkers for the diagnosis of neonatal infections. 
They reviewed 65 articles for statistical analysis with sensitivity, specificity and cut off values 
as noted in table 4 below.31  CRP is shown to be the most specific but least sensitive test. 
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Table 4 Performance of biomarkers 
 
CRP = C-reactive protein; PCT = procalcitonin; IL 6 = interleukin 6; IL-8 = interleukin 8; TNF- α = tumour necrosis 
factor-alpha 
Meem M, Joyanta K, Mortuza R, et al. Biomarkers for diagnosis of neonatal infections : A systematic analysis of their potential as a point-
of-care diagnostics. Journal of Global Health [Internet]. 2011 [cited 2016 June 2];1(2):201-209. Table 2, Sensitivity, specificity and cutt-off 
values of biomarkers in reviewed studies; p.204. Available from: Pubmed 
2.3.4. Point of care CRP studies 
Thirteen studies reviewing CRP point of care diagnostics were identified in this literature 
search. Only one of these studies took place in a developing country and only three studies 
focused specifically on neonates. The paediatric population was studied in the emergency 
departments of various hospitals. Table 5 reviews all thirteen studies and table 6 compares 
variables of the three most commonly used point of care CRP tests. 
 Of the thirteen studies tabulated: 
- Studies 1 to 8 reviewed CRP point of care tests against a reference laboratory CRP 
test 
- Studies 9 and 10 focused on using point of care CRP tests to distinguish between 
viral and bacterial infections without a reference test 
- Studies 11 and 12 compared various point of care CRP tests against each other 
- Study 13 focused on the cost-effectiveness of the point of care CRP test. 
These studies show that point of care CRP tests correlate well with standard laboratory CRP 
tests. However, for certain point of care tests, such as the QuikRead method, sensitivity and 
specificity may improve at higher cut off CRP values. Semi-quantitative point of care CRP 
methods are less costly, but not as precise or reliable as quantitative methods. The Afinion 
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analyser, a quantitative method, was practically more suitable and user-friendly than other 
point of care tests. The Afinion POCT was not specifically studied in the neonatal population. 
Most of these studies took place in the paediatric emergency medicine department where 
the point of care CRP was useful in distinguishing viral from bacterial infections in order to 
decide on whether or not to prescribe antibiotics. Although CRP is useful for discontinuing 
antibiotics in neonates with low risk of infection, studies have not quantified the impact of 
point of care testing on reducing antibiotic exposure. 
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Table 5 Point-of-care CRP test studies  
No. Authors Study population Aim POCT CRP test/s Conclusion 
1 
 
Diar et al 32 Neonates To validate a bedside CRP 
test against the laboratory 
CRP test 
QuikRead • QuikRead CRP can be used as a bedside tool 
• At cut off value of 16.2 mg/l QuikRead gives 
optimal agreement between it and the 
laboratory test 
• QuikRead CRP may improve availability of CRP 
results, reduce costs and facilitate earlier 
patient discharge in resource limited settings 
 
2 
 
Makhoul et al 33 Neonates To test whether fast 
complete blood count (CBC) 
and CRP significantly differ 
from conventionally 
measured CBC and CRP 
ABX-Micros 
analyser 
• ABX-Micros is equivalent to conventional 
methods only in measuring serum CRP levels 
but not CBC in suspected late onset sepsis 
• The mean difference between conventional 
test and point of care test was not statistically 
significant 
• Advantages of ABX-Micros: requires small 
volume of blood for testing and measures CRP 
within 4 minutes 
• Disadvantages of ABX-Micros: expensive and 
needs frequent calibration 
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No. Authors Study population Aim POCT CRP test/s Conclusion 
3 
 
Zecca et al 34 Neonates To compare the diagnostic 
accuracy between 2 rapid 
bedside tests for CRP with 
the laboratory method and 
their reliability 
Quick-Read 
NycoCard 
• Both rapid tests have excellent correlation 
against the reference laboratory method 
• The accuracy of both rapid tests is affected 
only by very high CRP concentrations, more 
evident with the NycoCard CRP test 
• Advantages of both tests: easy to use, require 
small volumes of blood for testing, and 
provide highly reliable results in under 5 
minutes 
• Useful for serial CRP measurements 
4 
 
Verbakel et al 35 Children 0-18 years To determine the analytical 
accuracy and user-
friendliness of the Afinion 
CRP test  
Afinion • Even at high CRP levels there was high 
agreement and precise measurements 
• Few differences between methods with low 
CRP levels were not statistically significant 
• Deemed user-friendly 
5 
 
Papaevangelou et 
al 36 
Children under 14 
years 
To use the QuickRead CRP 
in the paediatric emergency 
department and compare it 
to the standard laboratory 
method 
QuickRead  • QuickRead was reliable for rapid diagnosis 
• CRP was useful for distinguishing between 
bacterial and viral infections 
• A useful test to determine whether or not to 
admit a febrile child and whether or not to 
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No. Authors Study population Aim POCT CRP test/s Conclusion 
prescribe antibiotics for those discharged 
• QuickRead CRP was useful for deciding on the 
type of antibiotics in those with urinary tract 
infection, pneumonia or acute otitis media 
6 
 
Esposito et al 37 Children under 14 
years 
To compare the results of a 
rapid test for the bedside 
assay of CRP with those of 
standard laboratory assay 
samples in those attending 
the emergency department 
for acute respiratory 
infections 
QuikRead • Two methods showed good concordance 
• In children with respiratory tract infections, 
CRP concentrations greater than 70 mg/l are 
often due to bacteria and if less than 20 mg/l 
are usually viral in origin  
7 
 
Galetto-Lacour et 
al 38 
Infants 7 days to 36 
months 
To assess the value of 
bedside tests for predicting 
the occurrence of severe 
bacterial infections (SBI) in 
children with fever without 
source  
Not specified  • CRP and PCT performed better than IL-6 
• PCT less than 0.5 ng/l or CRP less than 40 mg/l 
almost rules out SBI 
• PCT has a slight advantage over CRP as it 
increases earlier after stimulation and has a 
better NPV 
8 
 
Ivaska et al 39 Children 0-16 years To investigate the analytical 
accuracy and feasibility of 
HemoCue WBC 
Afinion AS 100 
• Agreement between point of care test and 
laboratory methods for both WBC and CRP 
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No. Authors Study population Aim POCT CRP test/s Conclusion 
point of care tests for WBC 
and CRP at the paediatric 
emergency department  
CRP were sufficient for identifying children at risk 
of SBI 
• Precision of point of care test was less than 
laboratory test possibly due to blood sampling 
time differences and sampling methods 
(capillary versus venous sampling) 
9 
 
Marcus et al 40 Children 4-17 years To investigate the validity 
and feasibility of the 2 
minute Quick Read CRP test 
in the prediction of 
bacterial pneumonia in 
children in the emergency 
department 
Quick Read  • Quick Read CRP test was a useful predictor of 
bacterial pneumonia especially within 96 
hours from onset of symptoms 
• Mean CRP levels for bacterial pneumonia 
121.3 ± 122 mg/l 
• Mean CRP levels for viral pneumonia 27.2 ± 26 
mg/l 
10 
 
Marcus et al 41 Children 0-17 years To determine the clinical 
usefulness of the bedside 
Quick-Read CRP test for 
predicting bacterial 
gastroenteritis in the 
paediatric emergency 
department 
Quick-Read • CRP levels of ≥ 95 mg/l during the first 48 
hours of presentation suggest bacterial 
gastroenteritis  
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No. Authors Study population Aim POCT CRP test/s Conclusion 
11 
 
Brouwer et al 42 Not specified To review the assay 
performance and necessary 
pre-analytical handling of 
various available point of 
care CRP tests 
Semi-
quantitative 
methods – Actim 
CRP strips; 
Cleartest CRP 
strips 
 
Quantitative 
methods – 
QuikRead go; 
smart analyser; 
Afinion AS 100 
analyser; 
iChroma 
analyser; 
Microsemi; 
AQT90 Flex 
• In terms of analytical validation and practical 
evaluation Afinion and Smart CRP were most 
suitable 
• Afinion underestimated that CRP 
concentration by more than 10%, therefore 
Smart CRP was the preferred method 
• Quantitative methods favoured as an actual 
result is obtained, there is less hands-on time 
and the result does not have to be read-out 
immediately 
12 
 
Minnaard et al 43 Not specified To evaluate the analytical 
performance, agreement 
and user-friendliness of 
Afinion As 100  
NycoCard Reader 
II 
• Afinion, NycoCard Reader II, QuikRead go and 
QuikRead 101 showed better agreement with 
the laboratory test than the Eurolyser Smart 
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No. Authors Study population Aim POCT CRP test/s Conclusion 
several point of care CRP 
tests with a laboratory CRP 
test as the reference 
standard 
Eurolyser Smart 
700/340 CRP 
QuikRead go 
QuikRead 101 
700/340 
• With high CRP values agreement with the 
laboratory standard systematically decreased 
for all points of care tests 
• The Afinion test kit had the least chance of 
flaws in blood application  
• The Afinion and Eurolyser Smart 700/340 
analysers required the least separate actions 
13 
 
Hunter 44 Not specified To evaluate the cost 
effectiveness of CRP point 
of care test for respiratory 
tract infections in primary 
care 
Afinion  • Additional cost per patient of the point of care 
CRP test outweighs the cost saving and 
quality-adjusted life years associated with 
decrease in infections in the long-term 
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Table 6 Most commonly used point of care CRP tests  
Test Method Blood volume 
required 
Steps for 
procedure 
Time to result 
Afinion35 immunoturbidimetry 1.5 µl 3 steps 4 minutes 
QuikRead43 immunoturbidimetry 20 µl 7 steps 3 minutes 
NycoCard34 immunoturbidimetry 5 µl 5 steps 7 minutes 
 
It is estimated that between 11 and 23 uninfected neonates have received antibiotics for 
each documented bacterial infection within the neonatal intensive care unit.45 An ideal 
diagnostic test for neonatal sepsis may reduce antibiotic exposure. Several studies 
recommend the use of CRP to curtail antibiotic exposure. Low CRP levels 24 or 48 hours 
after presentation supports the discontinuation of antibiotics.45–47 Broad spectrum and long-
term antibiotic exposure is linked to production of multi-drug resistant gram negative bacilli 
and invasive candidiasis.48 The consequences of this may be high costs, unnecessary 
intravenous catheterisation or cannulation, separation of mother and infant, prolonged 
hospitalisation, high risk of colonisation by pathogenic organisms, emergence of drug-
resistant organisms, prescription and medication administration errors, intravenous 
infiltrates, alteration of gut flora, necrotising enterocolitis and death.45,49 The adverse 
effects of antibiotics also include nephrotoxicity, hepatotoxicity, ototoxicity, haematological 
abnormalities and iatrogenic anaemia due to frequent blood sampling.48  
2.3.5.  Conclusion 
Antibiotic stewardship ensures patient safety and quality of treatment, to combat the 
emergence of resistance and preserve the activity of our current antimicrobial agents. Some 
of the unique challenges facing neonatologists are the inability to obtain positive blood 
cultures in newborns as a result of antibiotics administered to mothers during the 
intrapartum period, the inability to obtain adequate blood culture samples, the difficulty in 
distinguishing between infection, colonisation or contamination by organisms and the 
establishment of appropriate treatment regimens for preterm neonates. Rational 
prescribing, employing antibiotic stewardship programs and ensuring that all members of 
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society take responsibility for the effective use of antibiotics are necessary. A reliable 
biomarker for neonatal sepsis forms one of the cornerstones of a successful antibiotic 
stewardship program.  
CRP as POCT is a quick, reliable and user-friendly method of obtaining a CRP result. This may 
assist in reducing antibiotic exposure and costs especially in resource limited settings. This 
may be especially useful in settings where significant delays in obtaining laboratory results 
occur.  
Most CRP POCT validity and prediction studies have been prospective observational or 
diagnostic test evaluation studies. Small sample sizes were evident in half of the reviewed 
studies. This may not have provided biologically or statistically representative groups to 
achieve study aims. The use of convenience sampling may have also introduced selection 
bias. Only three POCT studies focused specifically on the neonatal population. Most studies 
were performed in the paediatric emergency department, where point of care testing was 
used to differentiate between bacterial and viral infections for clinical management. Two 
studies did not compare each POCT to the gold standard but instead relied upon 
information provided by the manufacturer and comparison of findings of several random 
samples with the laboratory’s measurements. Studies predominantly relied on 
paediatricians or neonatologists trained to perform the POCT, to undertake testing. In some 
studies the operators of the POCT analysers were not stipulated. Only one POCT study was 
previously performed in South Africa, therefore the results of the other studies may not be 
generalised to the South African population. In this review only one study has specifically 
measured the cost-effectiveness of point of care testing. Studies that formally quantify the 
limitation of unnecessary antibiotic exposure by the utilisation of point of care testing are 
limited in the published literature especially in the neonatal population and none were 
found in this review. Future studies looking at this aspect are recommended.  
This research study offers specific evaluation of the Afinion CRP POCT in the South African 
neonatal intensive care unit setting against the standard laboratory measure. The use of 
junior clinicians in performing the rapid bedside tests ensures a more realistic outcome. The 
study also focuses on the use of CRP point of care testing to reduce antibiotic exposure by 
using time to results as a proxy measure. 
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3.2 Abstract 
 
Background 
Laboratory biomarkers are important adjuncts to clinical data in diagnosing neonatal sepsis. 
Available diagnostic tests often provide results 6 to 48 hours later. A bedside C-reactive 
protein (CRP) test may be able to exclude or diagnose sepsis within minutes.  
Objectives 
The objectives were to validate the Alere AfinionTM point of care test (POCT) CRP in a 
tertiary neonatal unit against the gold standard CRP assay in use by the National Health 
Laboratory service and to determine the difference in time to obtaining a result between 
the two systems. 
Methods 
A prospective observational study was conducted between February 2015 and June 2015. 
Neonates who were clinically indicated to undergo CRP testing were simultaneously tested 
using the POCT and laboratory assays. The sensitivities, specificities and predictive values for 
the POCT, with the laboratory test as the reference test were determined. The time to 
results between the two tests was compared.  
Results 
There were 139 measured CRP sample pairs from patients with suspected or proven 
neonatal sepsis. Using 10 mg/L as the cutoff value for both CRP tests, the sensitivity, 
specificity, positive predictive value and negative predictive value were 97.4%, 99%, 97.4% 
and 99% respectively. The area under the receiver operating characteristic curve was 0.99 
(p<0.001). The time to POCT result was 4 minutes. Laboratory results were registered at a 
mean of 4.7 hours but only checked after a mean of 6.8 hours. 
Conclusions 
The POCT CRP and laboratory CRP test have excellent correlation in neonates and may be a 
useful, quick, reliable method to rationalise antibiotic usage, reduce costs and allow for 
earlier patient discharge. 
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3.3 Background 
Neonatal sepsis is a clinical syndrome secondary to bloodstream invasion by bacteria 
resulting in circulatory compromise in the first 28 days of life. Neonatal sepsis is the third 
leading cause of neonatal deaths and is responsible for 10 % of all under-five mortality.1,2 
Predisposing factors for neonatal sepsis are prematurity, male gender, prolonged rupture of 
membranes and chorioamnionitis, maternal colonisation with Group B Streptococcus, 
maternal urinary tract infection and birth asphyxia.3 The clinical features of neonatal sepsis 
are often subtle and non-specific making diagnosis challenging. These features may be 
difficulty in feeding, convulsions, movement only when stimulated, bulging fontanelle, 
lethargy or irritability, hypotonia, tachypnoea, cyanosis, apnoea, severe chest indrawing, 
grunting, temperature instability, hypoglycaemia or hyperglycaemia, poor perfusion, 
petechiae or purpura, abdominal distension, hepatomegaly or unexplained jaundice.1,3–5 
Neonatal sepsis are classified as either early onset neonatal sepsis (EONNS), widely accepted 
as sepsis presenting in the first 72 hours of life and late onset neonatal sepsis (LONNS) 
which occurs after 72 hours of life. The distinction exists to assist in diagnosing the mode of 
transmission and most likely organisms causing the infection to focus antibiotic therapy. 
EONNS is as a result of intrapartum infection where LONNS are mostly hospital acquired 
infections associated with prolonged hospital stay, mechanical ventilation, indwelling 
catheters, parenteral nutrition and inadequate hand hygiene. 
Clinical information is mostly used to initiate treatment but is difficult to use to confirm 
sepsis or to tailor antibiotic therapy. The gold standard for diagnosing neonatal sepsis 
remains blood culture for bacteria, however blood culture positive rates vary widely and it 
often takes 24 to 48 hours to obtain a result.6,7 Biomarkers may be used to assist with 
diagnosis and management strategies for neonatal sepsis. While none are ideal, C-reactive 
protein (CRP) remains the preferred biomarker in many neonatal units due to it being the 
most extensively studied biomarker and its availability, rapidity and cost effectiveness.8 
CRP is an acute phase reactant synthesised in the liver and rapidly rises in 4 to 6 hours after 
the inflammatory process, reaching a peak in 36 hours and has a half life of 19 hours.9 The 
consensus for the upper limit of normal levels for CRP is 10 mg/l.8 A point of care test 
(POCT) is commercially available to provide bedside CRP measurements to be obtained 
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within minutes. This may assist with the reduction of antibiotic exposure as antibiotic 
stewardship is pivotal for patient safety, quality of treatment and reduction in antibiotic 
resistance however data of its application in the neonatal population is limited. 
3.4 Objectives 
The purpose of this study is to validate the Alere AfinionTM POCT CRP in neonates with 
suspected sepsis at Groote Schuur Hospital’s neonatal unit using the CRP from the gold 
standard laboratory assay as the reference test. The secondary objective is to measure the 
potential change in antibiotic dosage exposure if antibiotic therapeutic decisions were made 
using the CRP results from the Alere AfinionTM CRP system rather than the standard 
laboratory NHLS CRP test.  
3.5 Methods 
This was a prospective observational study and diagnostic test evaluation conducted from 
February 2015 to June 2015 at Groote Schuur Hospital neonatal unit, Cape Town, South 
Africa. Ethical approval for the study was approved by the Faculty of Health Sciences Human 
Research Ethics Committee of the University of Cape Town (HREC REF: 763/2014).  
Patients were recruited during normal working hours due to workforce limitations in both 
clinical and laboratory staffing after hours. 
We included any neonate in whom the CRP was performed between 8 am and 4 pm on 
weekdays as part of a septic work up or follow-up test and parental consent obtained. CRP 
measurements for both the Alere AfinionTM analyser and the standard laboratory analyser 
had to be available for eligibility. 
Neonates in whom parents denied consent or in whom the POCT CRP or standard laboratory 
result were not available were excluded. 
Patient names and hospital numbers were used to identify samples and data were recorded 
with the use of pre-designed data collection sheets. Patient demographics, risk factors for 
sepsis, clinical features of sepsis, reasons for requesting the CRP, blood culture results, use 
of empiric antibiotics, times of sampling and time to results as well as the POCT CRP and 
laboratory CRP were captured on the data collection sheets. Patients were noted to have 
suspected EONNS if clinical features of sepsis were found within the first 72 hours of life and 
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suspected LONNS if such features were noted after 72 hours of life. Clinicians involved in 
patient care within the neonatal unit were responsible for performing the tests and 
completing data collection sheets. The clinicians included medical interns, medical officers 
and registrars who received training to use the POCT analyser. Blood sampling was done at 
the clinician’s discretion through either venepuncture or arterial puncture. Blood for both 
CRP measurements were taken from the same sampling site and occasion. Laboratory CRP 
measurements were done by trained technicians based at the National Health Laboratory 
Service on the hospital’s premises using the Roche Cobas 6000 analyser and were blinded to 
the study and results. Therapeutic decisions were based solely on the standard laboratory 
CRP and not the POCT CRP result. 
The Alere AfinionTM POCT was utilised for this study as it only required 3 steps to perform 
the test, 1.5 µl of blood for testing and provides a CRP results within 4 minutes. The 3 steps 
for the point of care test are 1) collect the blood sample, 2) use the self-contained capillary 
tube in the test cartridge to collect the blood, and 3) insert the test cartridge into the 
analyser to obtain a CRP result. Both the POCT analyser and the laboratory analyser use 
immunoturbidimetry to obtain measurements. Immunoturbidimetry measures the 
absorbance of light from a sample where agglutination between latex particles coated with 
antibody and corresponding antigens on the CRP molecules take place. A quantitative CRP 
result is determined as the analyte concentration is inversely proportional to the light signal. 
The Alere AfinionTM control testing was performed as per manufacturer’s recommendations. 
The Alere AfinionTM has a CRP detection reference range of <5 to 200 mg/l, while the 
laboratory CRP has a range of <1 to 350 mg/l. A positive CRP result was noted to be >10 
mg/l for both tests.   
Data captured on hard copy data collection sheets were transferred to digital data collection 
sheets in EpiData® Manager (v2.0.0.25) and Entry Client (v2.0.1.11). Data were exported to 
Microsoft ® Excel ® 2013 (15.0.4841.1000) IBM ® SPSS R Statistics®23.0 and Stata® Statistical 
Software: Release 14 for analysis. 
Patient demographics are presented as either percentages of the total sample or medians 
with interquartile ranges, and minimum and maximum values. Risk factors and clinical 
features of sepsis are expressed through percentages and one or more variable per patient 
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may have been reported. Reasons for CRP testing are documented as percentages of the 
total sample. CRP test data are compared between the POCT CRP and the laboratory CRP 
though medians, ranges and quartiles. A scatter plot with appropriately constructed 
regression line indicates the degree of linearity between the two CRP test methods. The 
Bland-Altman plot was used to assess the absolute differences and means between the two 
CRP test methods. Sensitivities, specificities, negative predictive values (NPV), positive 
predictive values (PPV) for the POCT method and the laboratory and positive blood cultures 
were determined and their confidence intervals calculated. The sensitivity and specificity 
were combined in the receiver operating characteristic curves (ROC curves) and reported as 
the area under the curve with standard error of 95% confidence interval and p value. The 
statistical significance was taken as p <0.05. Time to POCT CRP and laboratory CRP results 
were compared using mean values. The time to results were used as a proxy measure for 
determining duration of antibiotic exposure. 
3.6 Results 
During the four month study period from February 2015 to June 2015, 158 paired CRP 
samples were taken for the study. 17 tests performed by the POCT analyser did not yield a 
CRP result and a further 2 CRP tests performed by the laboratory were insufficient for 
testing. Therefore 19 samples were excluded from the study and 139 CRP samples were 
included. More than one sample may have been obtained per patient during the study 
period on separate occasions, but each sample was regarded individually. A chart illustrating 
the study population is noted in Figure 1. Of the total sample population 61 (44%) had 
suspected EONNS and 78 (56%) had suspected LONNS.   
The demographic details are reported in table 1. About half of the study population were 
male (50.4%) with a preponderance for suspected LONNS (56.4%). The median age at CRP 
test was 5 days (interquartile range of 19 days) with minimum of 0 days and maximum of 68 
days. The median gestational age was 30 weeks (interquartile range of 6 weeks) with 
minimum of 24.7 weeks and maximum of 40.6 weeks. The median birth weight was 1340 g 
(interquartile range of 1091.5 g) with minimum of 620 g and maximum of 3795 g. 82.7% of 
the study population consisted of preterm newborns and 63% of the study population 
comprised of newborns with very low birth weight (≤1500g). 
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The reasons for requesting CRP tests were perinatal infection risk in 18%, neonatal signs and 
symptoms in 29.5%, follow-up CRP test for serial measurements in 51.5%, and in only one 
case was the reason not recorded. The top predisposing factors (table 2) selected in the 
entire study population include low birth weight (80.6%), preterm labour (33.8%), HIV 
exposure (15.1%), maternal fever (12.2%) and the presence of central or percutaneous 
invasive catheters (10.7%). Meconium aspiration syndrome (MAS) featured in the top five 
risk factors for suspected EONNS as it was documented in 13.1% of all noted risk factors. 
Parenteral nutrition (TPN) featured highly in suspected LONNS as it was selected in 6.4% of 
the risk factors.  
The clinical features of suspected sepsis (table 3) were variable depending on timing of 
suspected infection. In suspected EONNS the predominant clinical features were respiratory 
concerns (55.7%) and hyperglycaemia or hypoglycaemia (14.8%), but in a large group the 
patients were in fact asymptomatic (31.2%). In suspected LONNS the predominant clinical 
features were apnoea (38.5%), feeding issues (30.8%) and lethargy or irritability (20.5%). 
In terms of bacteriology, 127 blood cultures were performed, one of which was rejected, 
the reason for which was not recorded. The culture positivity rate was 7.1%. The blood 
cultures in EONNS and LONNS and isolated organisms are as documented in table 4.   
The median result of the POCT CRP and the laboratory test was <5 mg/l and 1.8 mg/l 
respectively. The range for the POCT CRP was <5 to 200 mg/l with first quartile <5 mg/l and 
third quartile 11.5 mg/l. The range for the laboratory CRP test was <1 to 247.2 mg/l with 
first quartile <1 mg/l and third quartile 10.8 mg/l. In looking at the agreement between the 
studied POCT and the reference test the simple regression plot is shown in figure 2 with y= -
0.0548 + 0.956x and 95% confidence intervals. The adjusted regression coefficient of 
determination (R2) was 0.97 with p <0.001. This implies that 97% of variability between the 
POCT and laboratory test has been accounted for. The estimated slope coefficient was 0.96 
with 95% confidence interval and p value <0.0001.  
The difference between the means of the two CRP tests, illustrated in the Bland-Altman plot 
(figure 3), is - 0.682 with 95% confidence interval for the mean difference -11.35 to 9.987. 
This indicates that the POCT is less than the laboratory test by 0.682 on average. At the cut 
off CRP level of 10 mg/l for both test methods the sensitivity, specificity, PPV and NPV were 
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97.4%, 99%, 97.4% and 99% respectively. The 95% confidence intervals for the 
aforementioned sensitivity, specificity, PPV and NPV were 84.6% to 99.9%, 93.8% to 99.9%, 
84.6% to 99.9% and 93.8% to 99.9% respectively. The POCT with cut off of 10 mg/l for CRP 
and positive blood cultures as a reference test showed that the sensitivity, specificity, PPV 
and NPV were 12.1%, 94.6%, 44.4% and 75.2% respectively and their confidence intervals 
were 4.5% to 29.1%, 87.3% to 98%, 15.4% to 77.3% and 66.2% to 82.5% respectively.   
The ROC curve (figure 4) assesses the accuracy of the POCT with the laboratory test as the 
reference test. The area under the curve is 0.993 (p <0.0001). 
Considering time to results, the Alere AfinionTM CRP test took 4 minutes to perform the test 
and obtain a result. In comparison the mean time to registering the laboratory result was 
4.7 hours with range from half an hour to 31.2 hours and the mean time to checking the 
laboratory result was 6.8 hours with range of 1.5 to 31 hours. 
3.7 Discussion 
Almost every text regarding neonatal sepsis will focus on describing it as a major health 
problem posing diagnostic, prognostic and management dilemmas. CRP is useful in 
confirming and excluding bacterial infection as a cause of neonatal illness. This study 
highlights a possible method to address some of the management and diagnostic dilemmas 
with specific focus on the reduction of antibiotic exposure in neonates. Between 11 and 23 
uninfected neonates are estimated to receive antibiotics for each documented bacterial 
infection within the neonatal intensive care unit.10 While empiric antibiotics are usually 
initiated in light of clinical findings, they are not without adverse effects or consequences 
relating to the patient, the family, the hospital and the wider community. They include toxic 
drug effects such as nephrotoxicity, hepatotoxicity, ototoxicity, haematological 
abnormalities, unnecessary blood sampling and venous cannulation, risk of colonisation by 
pathogenic organisms, alteration of gut flora, risk of necrotising enterocolitis and death, 
separation of infant from mother, prolonged hospitalisation, high health care costs and 
emergence of drug-resistant organisms.10,11   
CRP is useful, easily accessible in most settings, extensively studied and a cheaper test than 
most other biomarkers for infection. The Alere AfinionTM POCT CRP can be performed by the 
clinician, near the bedside with minimal blood volumes required for sampling and allowing 
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for rapid CRP determination. The linear regression and Bland-Altman plots showed good 
agreement between the two CRP test methods. The estimated slope coefficient of linear 
regression indicated that for every increase of 1 mg/l of the laboratory CRP measurement, 
there would be a corresponding 0.96 mg/l increase in the POCT measurement. When 
considering a cut off value of 10 mg/l for both CRP methods the sensitivity, specificity, PPV 
and NPV were all >95%. These results suggest that the CRP testing by the Alere Afinion TM 
analyser may be used as an alternative to the laboratory CRP analyser. It must be noted 
there were 17 episodes where the POCT CRP measurements were not available due to 
processing or machine errors. The error codes were displayed and grouped. In eight cases 
the haematocrit was too high or too low, in four cases there were capillary filling errors, in 
three cases there were test cartridge or analyser failures and two errors were not 
documented. 
The majority of these errors were due to human error or equipment failure. This suggests 
that more training sessions for staff and more frequent calibration of the analyser may be 
required.   
There are very few studies focusing on POCT CRP in the neonatal population and in 
particular the Alere AfinionTM CRP test in neonates. Often neonatal studies have small 
sample sizes and are European-based, which may not fit the South African context. The 
results of this study correlate well with previous studies but the Alere AfinionTM showed the 
best results against the reference test when compared to other point of care systems. Zecca 
et al reported that for cut off values of ≥10 mg/l for the bedside and laboratory CRP tests, 
sensitivities for the Quick-Read CRP and NycoCard CRP were 97.2% and 94.4% respectively 
and specificities for the Quick-Read and NycoCard CRP were  80.5% and 83.3% 
respectively.12 Diar and colleagues used a cut off value of 8 mg/l for the QuikRead CRP and 
10 mg/l for the laboratory CRP to determine sensitivity, specificity, PPV and NPV of 84%, 
80%, 30% and 97% respectively.13 The Alere AfinionTM CRP test may be favoured above 
other point of care tests as it has fewer steps or procedures to perform and requires less 
blood volume for testing than the Quick Read and NycoCard POCT CRP.   
Time to laboratory results were not specifically measured in any of the previous studies. In 
busy laboratories and neonatal units results are not made available or checked in optimal 
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time. Despite the National Health Laboratory Service being on the premises of the hospital 
where the study took place, it was apparent that the mean times to registering the result 
and the clinicians checking the result were almost 5 and 7 hours respectively. During this 
time the neonate may have received a dose of antibiotics that may otherwise have been 
discontinued in a newborn that had been tested by POCT CRP. 
The limitations of this study include reliance on doctors who regularly rotate through the 
department to record data and perform tests that may have led to information bias. Doctors 
may not have recorded all the correct predisposing factors, clinical features or 
measurements accurately. We used “time to obtaining result” as a proxy measure for 
potential reduction in antibiotic exposure when CRP was done to monitor antibiotic 
treatment. We did not record whether this translated into actual unnecessary antibiotic 
exposure. Furthermore this study took place within working hours when staff numbers are 
optimal and systems more efficient, which may have introduced selection bias. After hour 
emergency cases may mean sicker neonates, busier nights for fewer members of staff and 
longer time to laboratory results being registered and checked. 
3.8 Conclusion 
In resource limited settings with offsite laboratories, delayed time to laboratory CRP results, 
lack of blood culture result availability and financial constraints, the Alere AfinionTM POCT 
CRP may be a suitable alternative to the standard laboratory measure. Serial point of care 
CRP measuring are likely to assist with earlier discontinuation of antibiotic therapy in 
support of antibiotic stewardship. 
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3.10 Figures and Tables  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1: Study population 
 
 
 
 
 
 
 
 
 
158 paired CRP samples 
n = 139 samples after exclusion 
n = 19 samples excluded 
17 Alere Afinion tests not available because of - 8  errors due to haematocrit 
abnormalities - 4  capillary filling errors - 3  test cartridge or analyser failures - 2 errors not documented 
2 laboratory tests insufficient to perform test 
n = 61 (44%) 
Early onset neonatal sepsis 
n = 78 (56%) 
Late onset neonatal sepsis 
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Table 1: Patient Demographic Data 
Variable  All patients  Patients with suspected EONNS Patients with suspected LONNS 
n= 139   n=61 (44%)   n= 78 (56%) 
Sex 
Male  70 (50.4%) 26 (42.6%)  44 (56.4%) 
Female  69 (49.6%) 35 (57.4%)  34 (43.6%) 
 
Age at CRP test (days) 
 Median (IQR) 5 (19)  2 (3)   20 (25) 
 Range (min - max) 0-68  0-3   4-68 
 
Birth gestational age (weeks) 
 Median (IQR) 30 (6)  33 (8.6)   29 (3) 
 Range (min - max) 24.7-40.6  24.7-40.6   25-40 
Preterm  115 (82.7%) 44 (72.1%)  71 (91%) 
 Term  24 (17.3%)  17 (27.9%)  7 (9%) 
 
Birth weight (grams) 
 Median (IQR) 1340 (1091.5) 1320 (1360)  1340 (523.75) 
 Range (min - max) 620-3795  620-3795   630-3500 
 <1000g  36 (25.9%) 6 (9.8%)   30 (38.5%) 
 1001-1500g 51 (36.7%) 17 (27.9%)  34 (43.6%) 
 1501-2000g 17 (12.2%) 12 (19.7%)  5 (6.4%) 
 2001-2500g 11 (7.9%)  8 (13.1%)   3 (3.8%) 
 > 2500g  24 (17.3%) 18 (29.5%)  6 (7.7%) 
*IQR = interquartile range 
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Table 2: Positive risk factors for presumed sepsis in study population 
Risk factor Total patients Patients with suspected EONNS Patients with suspected LONNS 
   n=139  n=61 (44%)   n=78 (56%) 
BW <2500g  112 (80.6%) 41 (67.2%)    71 (91%) 
PROM   8 (5.7%)  5 (8.25%)   3 (6%) 
Difficult /  
prolonged labour  7 (5%)  5 (8.2%)    2 (2.6%) 
Maternal fever  17 (12.2%) 16 (26.2%)   1 (1.3%) 
Chorioamnionitis  4 (2.9%)  1 (1.6%)    3 (3.9%) 
Pre-term labour  47 (33.8%) 24 (39.3%)   23 (29.5%) 
MAS*    9 (6.5%)  8 (13.1%)   1 (1.28%) 
TPN*   5 (3.4%)  0    5 (6.4%) 
Formula feeds  4 (2.9%)  0    4 (5.1%) 
Central / long lines 14 (10.7%) 6 (9.8%)    8 (10.3%) 
HIV exposure  21 (15.1%) 10 (16.4%)   11 (14.1%) 
Post surgery  1 (0.7%)  0    1 (1.3%) 
MAS* = meconium aspiration syndrome; TPN* = total parenteral nutrition 
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Table 3: Clinical signs and symptoms for presumed sepsis 
Sign / Symptom Total patients Patients with suspected EONNS Patients with suspected LONNS 
   n=139  n=61 (44%)   n=78 (56%) 
Temperature instability 2 (1.4%)  1 (1.6%)    1 (1.3%)   
Hyper / hypoglycaemia 14 (10.1%) 9 (14.8%)   5 (6.4%) 
Apnoea   35 (25.2%) 5 (8.2%)    30 (38.5%) 
Cyanosis  7 (5%)  1 (1.6%)    6 (7.7%) 
Feeding issues  26 (18.7%) 2 (3.3%)    24 (30.8%) 
- abdominal distension 
- vomiting 
Lethargy / irritability  19 (13.7%) 3 (4.9%)    16 (20.5%) 
Neurological concerns 8 (5.8%)  5 (8.2%)    3 (3.9%) 
- seizures 
- bulging fontanelle  
Poor perfusion  0  0    0 
Coagulopathy  1 (0.7%)  0    1 (1.3%) 
Jaundice / hepatomegaly 11 (7.9%) 5 (8.2%)    6 (7.7%) 
Respiratory concerns 60 (43.2%) 34 (55.7%)   26 (33.3%) 
- increased oxygen requirements 
- respiratory distress 
Skin integrity   1 (0.7%)  0    1(1.3%) 
- wound dehiscence 
- skin infection 
Asymptomatic  24 (17.3%) 19 (31.2%)   5 (6.4%) 
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Table 4: Bacteriology of blood cultures 
Culture         N (% of total cultures) 
EONNS 
Total Positive        1 (0.8%) 
- Extended spectrum β-lactamase producing K. pneumoniae 
Total Negative        55 (43.3%) 
Rejected        1 (0.8%) 
Not done        4  
 
LONNS 
Total Positive        8 (6.3%) 
 - E.coli        2 
 - Extended spectrum β-lactamase producing K. pneumoniae  2 
 - Coagulase-Negative Staphylococcus    2 
 - Methicillin-resistant S. aureus     1 
 - Bacillus Cereus       1 
Total Negative        62 (48.8%) 
Rejected        0 
Not done        8  
K.pneumoniae = Klebsiella pneumoniae; E.coli = Escherichia coli; S. aureus = Staphylococcus aureus 
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Figure 2: Linear regression  
 
Figure 3: Bland-Altman plot 
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Figure 4: ROC curve  
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4.  Appendices 
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Addendum 1: Data collection sheet 
CRP POINT OF CARE RESEARCH PROJECT 
 
A) PATIENT DEMOGRAPHICS 
 
Date: 
 
Patient sticker 
 
Name of patient: 
 
Folder number:  
 
Sex:                       Date of birth:                    
 
Gestational age:  
 
Chronological age:  
 
Birth weight: 
 
Current weight: 
 
B) RISK FACTORS FOR SEPSIS 
 
1)  LBW  
 
2)  PROM  
  
3)  Difficult or prolonged labour  
 
4)  Maternal fever  
 
5)  Chorioamnionitis 
 
6)  Pre-term labour   
 
7)  Meconium aspiration   
 
8)  TPN   
 
9)  Formula feeds 
 
10)  Central /long lines  
 
11)  HIV exposure 
 
C) SIGNS AND SYMPTOMS OF SEPSIS 
 
1) Temperature instability 
 
2) Hyper/hypoglycaemia 
 
3) Apnoea 
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4) Cyanosis 
 
5) Feeding difficulties / abdominal distension / vomiting 
 
6) Lethargy / irritability 
 
7) Seizures / bulging fontanelle 
 
8) Poor perfusion 
 
9) Coagulopathy 
 
10) Jaundice / hepatomegaly 
 
11) Increased oxygen requirements / respiratory distress 
 
12) Wound dehiscence or skin infection  
 
13) Asymptomatic 
 
D) REASON FOR REQUESTING CRP 
 
1)  Perinatal risk for early neonatal sepsis 
 
2)  Neonatal signs/symptoms of sepsis  
 
 3)  Follow up CRP (hours after CRP initiation: ________________) 
 
E) BLOOD CULTURE TAKEN AND RESULT 
 
 RESULT 
YES  
 
NO  
OTHER CULTURES:  
 
 
F) EMPIRIC ANTIBIOTIC THERAPY 
 
1) Yes   2) No 
 
G) TIME FROM SAMPLING TO OBTAINING RESULTS 
 
POCT NHLS  
                         (in min)                              (in min) 
TIME OF SAMPLING: _____________________ TIME AT RESULT:  
POCT ________  
NHLS result released_____ result obtained____ 
 
H) CRP RESULT 
 
POCT NHLS 
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Addendum 2: Budget 
 
Item      Cost 
 
Test and control kits R10 000 
Printing and office consumables R1 500 
Research assistant R4 500 
Total R16 000 
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Addendum 3: 
Parental information: C-reactive protein as a tool for identifying infection 
 
We are doing a study on C-reactive protein.  This is a special protein made by the liver and found in 
the blood when there is infection or inflammation in the body. 
Infection in newborns is very serious and should be diagnosed and treated early.  Newborn babies 
don’t always show classic signs and symptoms of infection.  Subtle clinical clues and blood tests are 
helpful in diagnosing infection and starting and stopping antibiotics. 
What is this study all about? 
This study is comparing two ways to calculate this special protein.  The first way is a test done by the 
laboratory. The second way is a test done by an analyser in the nursery.   
Usually when we are concerned about infection we take blood from your baby and send it to the 
laboratory for tests, including the C-reactive protein test.  In our study the blood will not only be 
sent to the laboratory but will be analysed in the nursery within a few minutes.  This quick test will 
give us a value which we can compare to the laboratory value.   
The blood for both the laboratory and nursery analyser tests will be taken at the same time.  The 
nursery analyser needs a small volume of additional blood (1.5 µl) to run the test.  
Participation in the study is completely voluntary.  Medical information recorded will be kept 
confidential.  The results from this study may be published in a medical journal.  If you no longer 
wish to participate in this study, you may withdraw your baby from it at anytime.  This will not at all 
affect how we care for your baby.  
How will this study help my baby and others? 
The quick test done by the analyser in the nursery will be able to give us a result within minutes.  For 
the duration of this study only the result from the laboratory will be used to determine further 
management of your child.  We hope to use our results from this study to make future testing 
quicker, simpler and possibly cheaper and improve quality of care to infants  
Who is doing this study? 
Dr Yaseen Joolay and Dr Kim Prince will be responsible for carrying out this study.  Should you have 
any queries about the study, you may contact us on 021 404 6069.  
Please note that the Human Research Ethics Committee of the University of Cape Town has granted 
approval for this research.  Should you have any ethical concerns, do not hesitate to contact the 
committee on 021 406 6492.
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Consent form 
 
I ………………………………….., the parent of …………………………………… have read and discussed this form 
with the researchers and understand what the research project entitled: “A comparison of standard 
CRP laboratory measurement to point of care testing CRP in a neonatal intensive care unit setting” is 
about. 
 
My questions have been answered. 
 
I freely agree (tick the appropriate block):  
 
□  To take part in the study 
□  I confirm that I have read and understand the information on the sheet provided. I have had 
the opportunity to ask questions 
□  I understand that my participation in this study is voluntary and I may withdraw at any time 
□  I agree that the data collected may be stored and used for future research 
 
 
__________________________ __________________ _______________ 
Name of parent   Signature   Date 
 
__________________________ __________________ _______________ 
Name of researcher  Signature   Date 
 
__________________________ __________________ _______________ 
Name of witness  Signature   Date 
69 
Letter of Ethical Approval 
 70 
 
 
 71 
 
Instructions to authors of chosen journal: South African Medical Journal (SAMJ) 
 
Author Guidelines 
Accepted manuscripts that are not in the correct format specified in these 
guidelines will be returned to the author(s) for correction, and will delay 
publication. 
 
AUTHORSHIP 
Named authors must consent to publication. Authorship should be based on: (i) substantial 
contribution to conception, design, analysis and interpretation of data; (ii) drafting or critical 
revision for important intellectual content; or (iii) approval of the version to be published. 
These conditions must all be met (uniform requirements for manuscripts submitted to 
biomedical journals; refer to www.icmje.org). 
 
CONFLICT OF INTEREST 
Authors must declare all sources of support for the research and any association with a 
product or subject that may constitute conflict of interest. 
 
RESEARCH ETHICS COMMITTEE APPROVAL 
Provide evidence of Research Ethics Committee approval of the research where relevant. 
 
PROTECTION OF PATIENT'S RIGHTS TO PRIVACY 
Identifying information should not be published in written descriptions, photographs, and 
pedigrees unless the information is essential for scientific purposes and the patient (or 
parent or guardian) gives informed written consent for publication. The patient should be 
shown the manuscript to be published. Refer to www.icmje.org. 
 
ETHNIC CLASSIFICATION 
References to ethnic classification must indicate the rationale for this. 
 
MANUSCRIPTS 
Shorter items are more likely to be accepted for publication, owing to space constraints and 
reader preferences. 
Research articles (previously 'Original articles') not exceeding 3 000 words, with up to 6 
tables or illustrations, are usually observations or research of relevance to clinical medicine 
and related fields. References should be limited to no more than 15. Please 
provide a structured abstract not exceeding 250 words, with the following recommended 
headings: Background, Objectives, Methods, Results, and Conclusion. 
Scientific letters will be considered for publication as shorter Research articles.  
Editorials, Opinions, etc. should be about 1000 words and are welcome, but unless invited, 
will be subjected to the SAMJpeer review process. 
Review articles are rarely accepted unless invited. 
Letters to the editor, for publication, should be about 400 words with only one illustration 
or table, and must include a correspondence address. 
Forum articles must be accompanied by a short description (50 words) of the affiliation 
details/interests of the author(s). Refer to recent forum articles for guidance. Please provide 
an accompanying abstract not exceeding 150 words. 
Book reviews should be about 400 words and must be accompanied by the publication 
details of the book. 
Obituaries should be about 400 words and may be accompanied by a photograph. 
 72 
 
Guidelines must be endorsed by an appropriate body prior to consideration and all conflicts 
of interest expressed. A structured abstract not exceeding 250 words (recommended sub-
headings: Background, Recommendations, Conclusion) is required. Sections and 
sub-sections must be numbered consecutively (e.g. 1. Introduction; 1.1 Definitions; 2. etc.) 
and summarised in a Table of Contents. References, appendices, figures and tables must be 
kept to a minumum. 
Guidelines exceeding 8 000 words will only be considered for publication as 
a supplement to the SAMJ; the costs of which must be covered by 
sponsorship or advertising. The Editor reserves the right to determine the 
scheduling of supplements. Understandably, a delay in publication must be 
anticipated dependent upon editorial workflow. 
  
MANUSCRIPT PREPARATION 
Refer to articles in recent issues for the presentation of headings and subheadings. If in 
doubt, refer to 'uniform requirements' - www.icmje.org. Manuscripts must be provided 
in UK English. 
Qualification, affiliation and contact details of ALL authors must be provided in the 
manuscript and in the online submission process. 
Abbreviations should be spelt out when first used and thereafter used consistently, e.g. 
'intravenous (IV)' or 'Department of Health (DoH)'. 
Scientific measurements must be expressed in SI units except: blood pressure (mmHg) 
and haemoglobin (g/dl). Litres is denoted with a lowercase 'l' e.g. 'ml' for millilitres). Units 
should be preceded by a space (except for %), e.g. '40 kg' and '20 cm' but '50%'. 
Greater/smaller than signs (> and 40 years of age'. The same applies to ± and º, i.e. '35±6' 
and '19ºC'. 
Numbers should be written as grouped per thousand-units, i.e. 4 000, 22 160... 
Quotes should be placed in single quotation marks: i.e. The respondent stated: '...' 
Round brackets (parentheses) should be used, as opposed to square brackets, which are 
reserved for denoting concentrations or insertions in direct quotes. 
General formatting The manuscript must be in Microsoft Word or RTF document format. 
Text must be single-spaced, in 12-point Times New Roman font, and contain no 
unnecessary formatting (such as text in boxes, with the exception of Tables). 
 
ILLUSTRATIONS AND TABLES 
If tables or illustrations submitted have been published elsewhere, the author(s) should 
provide consent to republication obtained from the copyright holder. 
Tables may be embedded in the manuscript file or provided as 'supplementary files'. 
They must be numbered in Arabic numerals (1,2,3...) and referred to consecutively in the 
text (e.g. 'Table 1'). Tables should be constructed carefully and simply for intelligible data 
representation. Unnecessarily complicated tables are strongly discouraged. Tables must be 
cell-based (i.e. not constructed with text boxes or tabs), and accompanied by a concise title 
and column headings. Footnotes must be indicated with consecutive use of the following 
symbols: * † ‡ § ¶ || then ** †† ‡‡ etc. 
Figures must be numbered in Arabic numerals and referred to in the text e.g. '(Fig. 1)'. 
Figure legends: Fig. 1. 'Title...' All illustrations/figures/graphs must be of high 
resolution/quality: 300 dpi or more is preferable, but images must not be resized to 
increase resolution. Unformatted and uncompressed images must be attached individually 
as 'supplementary files' upon submission (not solely embedded in the accompanying 
manuscript). TIFF and PNG formats are preferable; JPEG and PDF formats are accepted, but 
authors must be wary of image compression. Illustrations and graphs prepared in Microsoft 
Powerpoint or Excel must be accompanied by the original workbook. 
 
REFERENCES 
References must be kept to a maximum of 15. Authors must verify references from 
original sources. Only complete, correctly formatted reference lists will be 
 73 
 
accepted. Reference lists must be generated manually and not with the use of reference 
manager software. Citations should be inserted in the text as superscript numbers between 
square brackets, e.g. These regulations are endorsed by the World Health 
Organization,[2] and others.[3,4-6] All references should be listed at the end of the article in 
numerical order of appearance in the Vancouver style (not alphabetical order). Approved 
abbreviations of journal titles must be used; see the List of Journals in Index Medicus. 
Names and initials of all authors should be given; if there are more than six authors, the 
first three names should be given followed by et al. First and last page, volume and issue 
numbers should be given. 
Wherever possible, references must be accompanied by a digital object identifier 
(DOI) link and PubMed ID (PMID)/PubMed Central ID (PMCID). Authors are 
encouraged to use the DOI lookup service offered by CrossRef. 
Journal references: Price NC, Jacobs NN, Roberts DA, et al. Importance of asking about 
glaucoma. Stat Med 1998;289(1):350-355. [http://dx.doi.org/10.1000/hgjr.182] [PMID: 
2764753] 
Book references: Jeffcoate N. Principles of Gynaecology. 4th ed. London: Butterworth, 
1975:96-101. Chapter/section in a book: Weinstein L, Swartz MN. Pathogenic 
Properties of Invading Microorganisms. In: Sodeman WA jun, Sodeman WA, eds. Pathologic 
Physiology: Mechanisms of Disease. Philadelphia: WB Saunders, 1974:457-472. 
Internet references: World Health Organization. The World Health Report 2002 - Reducing 
Risks, Promoting Healthy Life. Geneva: World Health Organization, 2002. 
http://www.who.int/whr/2002 (accessed 16 January 2010). 
Other references (e.g. reports) should follow the same format: Author(s). Title. Publisher 
place: publisher name, year; pages. Cited manuscripts that have been accepted but not yet 
published can be included as references followed by '(in press)'. Unpublished observations 
and personal communications in the text must not appear in the reference list. The full 
name of the source person must be provided for personal communications e.g. '...(Prof. 
Michael Jones, personal communication)'. 
 
PROOFS 
A PDF proof of an article may be sent to the corresponding author before publication to 
resolve remaining queries. At that stage, only typographical changes are permitted; the 
corresponding author is required, having conferred with his/her co-authors, to reply within 2 
working days in order for the article to be published in the issue for which it has been 
scheduled. 
 
CHANGES OF ADDRESS 
Please notify the Editorial Department of any contact detail changes, including email, to 
facilitate communication. 
 
CPD POINTS 
Authors can earn up to 15 CPD CEUs for published articles. Certificates may be requested 
after publication of the article. 
 
CHARGES 
There is no charge for the publication of manuscripts. 
Please refer to the section on 'Guidelines' regarding the publication of supplements, where 
a charge may be applicable. 
  
Submission Preparation Checklist 
As part of the submission process, authors are required to check off their submission's 
compliance with all of the following items, and submissions may be returned to authors that 
do not adhere to these guidelines. 
 74 
 
1. Named authors consent to publication and meet the requirements of authorship as set 
out by the journal. 
2. The submission has not been previously published, nor is it before another journal for 
consideration. 
3. The text complies with the stylistic and bibliographic requirements in Author 
Guidelines. 
4. The manuscript is in Microsoft Word or RTF document format. The text is single-
spaced, in 12-point Times New Roman font, and contains no unnecessary formatting. 
5. Illustrations/figures are high resolution/quality (not compressed) and in an acceptable 
format (preferably TIFF or PNG). These must be submitted individually as 
'supplementary files' (not solely embedded in the manuscript). 
6. For illustrations/figures or tables that have been published elsewhere, the author has 
obtained written consent to republication from the copyright holder. 
7. Where possible, references are accompanied by a digital object identifier (DOI) and 
PubMed ID (PMID)/PubMed Central ID (PMCID). 
8. An abstract has been included where applicable. 
9. The research was approved by a Research Ethics Committee (if applicable) 
10. Any conflict of interest (or competing interests) is indicated by the author(s). 
  
Copyright Notice 
The South African Medical Journal (SAMJ) reserves copyright of the material 
published. The work is licensed under a Creative Commons Attribution - Noncommercial 
Works License. Material submitted for publication in the SAMJ is accepted provided it has 
not been published or submitted for publication elsewhere. The SAMJ does not hold itself 
responsible for statements made by the authors. 
  
Privacy Statement 
The SAMJ is committed to protecting the privacy of the users of this journal website. The 
names, personal particulars and email addresses entered in this website will be used only 
for the stated purposes of this journal and will not be made available to third parties without 
the user’s permission or due process. Users consent to receive communication from 
theSAMJ for the stated purposes of the journal. Queries with regard to privacy may be 
directed to publishing@hmpg.co.za. 
  
   
 
 
 
The South African Medical Journal | Online ISSN: 2078-5135 | Print ISSN: 0256-9574 | © 2014 Health & Medical Publishing Group  
This journal is protected by a Creative Commons Attribution - NonCommercial Works License (CC BY-NC 3.0) | Read our privacy policy. 
Our Journals: South African Medical Journal | African Journal of Health Professions Education | South African Journal of Bioethics and Law | 
 South African Journal of Child Health | Southern African Journal of Critical Care | Southern African Journal of HIV Medicine |  
South African Journal of Obstetrics and Gynaecology | 
 
 
 
 75 
 
5.  Acknowledgements 
 
I sincerely wish to thank Dr Yaseen Joolay, who supervised this research study and edited this mini-
dissertation. His encouragement and assistance were invaluable. 
Thanks and acknowledgement to Dr Fierdoz Omar for her contribution regarding laboratory testing 
methods and data representation. 
I wish to acknowledge the medical team at Groote Schuur Hospital neonatal unit who assisted in 
carrying out the study. 
Thanks and acknowledgement to the Alere Health Care Company for lending the analyser for the 
duration of the study and assisting with training on how to use the point of care system. 
Thanks to the National Health Laboratory Service for the use of their database to check times to 
registered results. 
I wish to thank Mr Robert Prince for his invaluable statistical support, education and incredible 
mathematical mind. 
I wish to thank Quanta Gauld from the University of Cape Town Writing Centre who assisted with 
proof reading this mini-dissertation. 
I am thankful for the support of my family and friends, particularly my father Robert Prince and 
mother Rachel Prince who helped me realise my potential in order to carry out my dream career. 
Their support throughout my career has been extraordinary.   
 
  
 
 
 
 
 
 
